CIK: 0001910264 · Show all filings
Period: Q3 2025 (← Previous) (Next →)
Filing Date: Nov 12, 2025
Total Value ($000): $691,412 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | 2,346,630 | $192,658 | 27.9% | $16.72 | +330.6% | Common Stock | 03940C100 |
| CRSP | CRISPR Therapeutics AG | 2,038,763 | $132,132 | 19.1% | $64.71 | -11.3% | Common Shares | H17182108 |
| ZBIO | Zenas BioPharma, Inc | 4,911,539 | $109,036 | 15.8% | $17.98 | -9.5% | Common Stock | 98937L105 |
| MLYS | Mineralys Therapeutics Inc. | 2,113,933 | $80,160 | 11.6% | $14.62 | +47.9% | Common Stock | 603170101 |
| ORIC | ORIC Pharmaceuticals, Inc. | 4,514,929 | $54,179 | 7.8% | $6.71 | +56.7% | Common Stock | 68622P109 |
| DSGN | Design Therapeutics, Inc. | 6,526,476 | $49,144 | 7.1% | $16.67 | -70.0% | Common Stock | 25056L103 |
| SPRY | ARS Pharmaceuticals, Inc. | 4,012,903 | $40,330 | 5.8% | $6.79 | +111.5% | Common Stock | 82835W108 |
| ORKA | Oruka Therapeutics, Inc | 430,330 | $8,275 | 1.2% | $33.46 | -55.7% | Common Stock | 687604108 |
| ALMS | Alumis Inc. | 1,959,896 | $7,820 | 1.1% | $13.30 | -69.0% | Common Stock | 022307102 |
| NKTX | Nkarta, Inc. | 3,333,333 | $6,900 | 1.0% | $11.49 | -82.1% | Common Stock | 65487U108 |
| OCS | Oculis Holding AG | 322,500 | $5,670 | 0.8% | $20.50 | -13.5% | Ordinary Shares | H5870P102 |
| ENGN | enGene Holdings Inc. | 747,750 | $5,107 | 0.7% | $11.04 | -58.7% | Common Shares | 29286M105 |